[1] Marzi L, Combes E, Vie N, et al.FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer[J]. Br J Cancer,2016,115(10):1223-33. [2] 钟振,刘益飞,刘俊华.FOXO3a基因在癌症中的研究进展[J].中国肿瘤外科杂志,2013,5(3):184-186. [3] 刘鑫,胡皆乐,李佑,等.FOXO3在结直肠癌组织中的表达及临床意义[J].实用癌症杂志,2016,31(11):1773-1777. [4] 胡珊珊,宋彦,罗玉明,等.MiR-150-5p靶向HIF1α调控结直肠癌细胞西妥昔单抗耐药的相关机制研究[J].四川医学,2020,41(7):688-691. [5] 苏昊,刘文杰,包满都拉,等.转移性结直肠癌西妥昔单抗耐药的分子机制[J].国际肿瘤学杂志,2020,47(5):308-311. [6] 吴军,计骏,张俊,等.结肠癌K-ras突变与对西妥昔单抗耐药的实验研究[J].外科理论与实践,2009,14(4):396-402. [7] Zhou J, Ji Q, Li Q.Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies[J]. J Exp Clin Cancer Res,2021,40(1):328. [8] 方庆亮,董昌盛,陈荣,等.SIRT3/FOXO3通路在肺癌A549细胞放疗抵抗中的作用机制研究[J].中国现代医学杂志,2021,31(12):28-34. [9] 滕春媛,李梅,范清玲.常规化疗方案联合西妥昔单抗治疗消化道肿瘤的效果分析[J].医药前沿,2021,11(27):90-91. [10] 熊峰,陶敏,段卫明,等.西妥昔单抗联合伊立替康三线治疗晚期结直肠癌的疗效观察[J].中华肿瘤防治杂志,2008,15(22):1759-1760. [11] Ferber E C, Peck B, Delpuech O, et al.FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression[J]. Cell Death Differ 2012,19(6):968-979. |